Merz Appoints Bob Rhatigan as President and Chief Executive Officer in North America
Merz Pharma, a global leader in aesthetics and neurotoxins, today announced the appointment of Bob Rhatigan as President and Chief Executive Officer (CEO) of Merz North America and Patrick Urban as Chief Commercial Officer, effective immediately. Both Mr. Rhatigan and Mr. Urban will be based in Raleigh, NC.
“The global leadership team and I have great confidence that Bob Rhatigan has the strategic vision, extensive industry knowledge and operational experience that is needed to drive growth and lead Merz North America to continued success,” said Philip Burchard, CEO of Merz Pharma. “He has a proven track record of accomplishments and unparalleled experience that bring great benefit to our company’s aesthetics and neurotoxins portfolio. Bob also brings a personal style that is fully aligned with our values and culture, making him a natural fit for the team.”
In his new role, Mr. Rhatigan will assume responsibility for Merz’s business in North America, leading strategy and operations across the US and Canada. Mr. Rhatigan will join Merz’s global management board and will report directly to Philip Burchard, CEO of Merz Pharma Group.
Prior to joining Merz, Mr. Rhatigan served as Senior Vice President of Allergan’s Facial Aesthetics business, overseeing the US launches and commercial success of their key aesthetic injectable brands and growing the division into a $700M business. While at Allergan, he also served as Senior Vice President, General Manager and Chief Executive of SkinMedica, leading all aspects of the global SkinMedica business as well as the integration of SkinMedica into Allergan. Most recently, Bob Rhatigan served as President and Chief Operating Officer at Alphaeon Corporation, a healthcare company focused on the lifestyle medical space.
“I am honored and excited to lead the Merz North America team to an even higher level of achievement and ensure a successful future for the organization. We have a well-rounded and strong portfolio in which I see clear potential,” said Mr. Rhatigan. “I am fortunate to work with a deeply experienced senior leadership team as we continue to target innovative approaches and growth opportunities with a strategic focus on our aesthetics and neurotoxins business. We will remain committed to being a trusted partner for our customers to provide long-term value as well as meet the evolving needs of our patients.”
In addition, Patrick Urban, who most recently served as interim President and CEO for Merz North America, has accepted the role of Chief Commercial Officer, reporting directly to Bob Rhatigan. In this newly-created position, Mr. Urban will play a critical role in driving the commercial success of the Merz Aesthetics portfolio.
Mr. Urban brings more than 20 years of commercial experience in the U.S. pharmaceutical and medical device industries to his new role as Chief Commercial Officer. Previously, Urban held the role of Vice President, US Aesthetics Sales, where he was responsible for the management of Merz North America’s U.S.-based aesthetics sales force. Prior to joining Merz, Patrick Urban served as Vice President, U.S. Sales for Ulthera, Inc., joining Ulthera in October 2009 as the organization’s first sales leader, serving as a key conduit between Ulthera‘s National Accounts team, OUS sales force and Global Marketing function.
As Merz’s largest subsidiary, Merz North America is a significant contributor to the company’s global business in both aesthetics and neurotoxins. Merz North America is headquartered in Raleigh, North Carolina, with additional locations in Mesa, Arizona, Franksville, Wisconsin and Toronto, Canada.
About Merz Pharma Group
With approximately 3,000 employees and 34 subsidiaries worldwide, Merz is a global leader in Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. Complementing its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy for the treatment of movement disorders. Skincare products and a range of OTC medicines are also included in offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2015/16, Merz Pharma Group generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Merz North America
Phone: +1 919.582.8114
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom